Showing posts with label neuroscience. Show all posts
Showing posts with label neuroscience. Show all posts

Thursday, January 3, 2013

Stride Made in Understanding Memory

A study submitted to the journal Nature on 16 August 2012 overturns a longheld model of long-term memory formation with the discovery that the protein kinase M, zeta enzyme (PKM-ζ) is not necessary as part of a cellular correlate of learning and memory potentiation/longevity. It was conducted by Lenora J. Volk, Julia L. Bachman, Richard Johnson, Yilin Yu and Richard L. Huganir of the Department of Neuroscience in Howard Hughes Medical Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland.

The abstract notes, "Inhibiting PKM-ζ activity using a synthetic zeta inhibitory peptide (ZIP) based on the PKC-ζ pseudosubstrate sequence reverses established [long-term potentiation (LTP)] in vitro and in vivo. More notably, infusion of ZIP eliminates memories for a growing list of experience-dependent behaviours, including active place avoidance, conditioned taste aversion, fear conditioning and spatial learning. However, most of the evidence supporting a role for PKM-ζ in LTP and memory relies heavily on pharmacological inhibition of PKM-ζ by ZIP. To further investigate the involvement of PKM-ζ in the maintenance of LTP and memory, we generated transgenic mice lacking PKC-ζ and PKM-ζ. We find that both conventional and conditional PKC-ζ/PKM-ζ knockout mice show normal synaptic transmission and LTP at Schaffer collateral–CA1 synapses, and have no deficits in several hippocampal-dependent learning and memory tasks. Notably, ZIP still reverses LTP in PKC-ζ/PKM-ζ knockout mice, indicating that the effects of ZIP are independent of PKM-ζ."

Researchers Stimulate Brain's Own Painkillers With Electricity

Alexandra DaSilva and colleagues from the University of Michigan, Harvard University and the City University of New York stimulated the brain's endogenous supply of morphine to target areas in patients suffering from chronic, severe facial pain using sensitive electrodes in a study published on 2 November 2012. This is excellent news, because the possible practice of using electricity to stimulate our own endogenous painkilling opioid drugs logically reduces our dependency on external sources of the same drug.

Writes the University of Michigan's Laura Bailey, "DaSilva and colleagues intravenously administered a radiotracer that reached important brain areas in a patient with trigeminal neuropathic pain (TNP), a type of chronic, severe facial pain. They applied the electrodes and electrically stimulated the skull right above the motor cortex of the patient for 20 minutes during a PET scan (positron emission tomography). The stimulation is called transcranial direct current stimulation (tDCS).

"The radiotracer was specifically designed to measure, indirectly, the local brain release of [morphine], a natural substance that alters pain perception. In order for [an] opiate to function, it needs to bind to the mu-opioid receptor [of which the study assessed the levels.]

"The dose of electricity is very small, he says. Consider that electroconvulsive therapy (ECT), which is used to treat depression and other psychiatric conditions, uses amperage in the brain ranging from 200 to 1600 milliamperes (mA). The tDCS protocol used in DaSilva's study delivered 2 mA, considerably lower than ECT.

"Just one session immediately improved the patient's threshold for cold pain by 36 percent, but not the patient's clinical, TNP/facial pain. This suggests that repetitive electrical stimulation over several sessions are required to have a lasting effect on clinical pain, DaSilva says."